{"id":"https://genegraph.clinicalgenome.org/r/29890dfa-6e69-46fa-9217-a4258b24e8b0v1.0","type":"EvidenceStrengthAssertion","dc:description":"*UGDH* was first reported in relation to autosomal dominant congenital heart disease in 2009 (Smith et al., PMID: 19506109). At least two unique missense variants were reported in three probands with atrioventricular septal defects (PMID: 19506109). This gene-disease relationship is also supported by expression data in mouse embryos and two zebrafish models (PMID: 11533493, 22815472, 22815472). In summary, the evidence supporting the relationship between *UGDH* and autosomal dominant congenital heart disease has been disputed and no valid evidence remains to support the claim. More evidence is needed to either support or entirely refute the role *UGDH* plays in this disease. This classification was approved by the ClinGen Congenital Heart Disease GCEP on the meeting date June 10th, 2024 (SOP Version 10).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/29890dfa-6e69-46fa-9217-a4258b24e8b0","GCISnapshot":"https://genegraph.clinicalgenome.org/r/ecce1706-83f5-4a2e-8f15-3a2207972a69","calculatedEvidenceStrength":"Limited","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/ecce1706-83f5-4a2e-8f15-3a2207972a69_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10130","date":"2024-08-21T12:32:02.353Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/ecce1706-83f5-4a2e-8f15-3a2207972a69_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10130","date":"2024-06-10T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"No convincing variants were observed in human patients.","curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ecce1706-83f5-4a2e-8f15-3a2207972a69_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ecce1706-83f5-4a2e-8f15-3a2207972a69_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07df1ec5-ce9f-4c6e-b51c-b1207d4c0941","type":"EvidenceLine","dc:description":"Downgraded as this model is a MO zebrafish model which also is not consistent with the mode of inheritance of disease in human ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de63d260-e2a0-4e63-86f6-384f07c975b7","type":"Finding","dc:description":"The AV border cells do not differentiate from their neighbors in jekyll mutants, suggesting that jekyll is required in a cell signaling event that establishes a boundary between the atrium and the ventricle. Jekyll mutant embryos also exhibit pericardial edema and toggling of blood between the two chambers of the heart which is indicative of defective AV valve function","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11533493","rdfs:label":"Walsh and Stainier MO zebrafish","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/25b641f6-1f5a-4aba-b5c4-65aa2dd69508","type":"EvidenceLine","dc:description":"The rescue was not scored as the variants were too frequent in gnomAD v4. to be pathogenic in human. However, the model showed some endocardial defects after MO knockdown of ugdh, so it was scored at 1 pt.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11e8087b-e7f5-45ee-bf40-dcad31bdd8ee","type":"Finding","dc:description":"The endocardial ring is clearly visible in wt but not ugdh MO fish. Coinjection of wt UGDH mRNA with ugdh MO restored formation of the endocardial ring while coinjection of ugdh MO and UGDH mutant R141C or E416D did not rescue endocardial ring formation. Both polymorphisms severely compromised the ugdh enzymeâ€™s activity in vivo and were observed in AVSD patients (PMID: 19506109) but they were too frequent in gnomAD v4. to be pathogenic\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22815472","rdfs:label":"Hyde MO Zebrafish","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ecce1706-83f5-4a2e-8f15-3a2207972a69_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84fc6d5c-544a-4ce1-8cca-f8e6e4f8ced9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6c6825d-ff57-4448-8b4d-14d43f9127aa","type":"Finding","dc:description":"in situ hybridization showed that Ugdh was expressed at sites of endocardial cushion formation preceding valve morphogenesis during mouse heart development. At E11.5, strong expression of Ugdh was observed in the endocardial cushions located within the AV canal. At E12.5, Ugdh mRNA was present in the endocardial cushions of the AV canal, in the dorsal mesenchymal protrusion and in the outflow tract cushions. At E14.5, specific expression of Ugdh was observed in the valve leaflets located in the AV canal, which eventually become the leaflets of the mitral and tricuspid valves. Ugdh expression was not detectable in myocardium","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22815472","rdfs:label":"Mouse embryo expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/ecce1706-83f5-4a2e-8f15-3a2207972a69_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db5d075b-103c-411a-a25b-9f6deb82e2b0","type":"EvidenceLine","dc:description":"gnomAD v.4 MAF was 0.02081 (616/29598, 5 homozygotes) in Ashkenazi Jewish which is too frequent to be pathogenic (>0.00001)","calculatedScore":0.5,"direction":"Contradicts","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db5d075b-103c-411a-a25b-9f6deb82e2b0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Thermally sensitive fluorescence assay showed that protein stability is compromised by the variants that occur at the dimer interface (PMID: 22815472)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/db5d075b-103c-411a-a25b-9f6deb82e2b0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19506109","allele":{"id":"https://genegraph.clinicalgenome.org/r/8488f432-e708-4f1f-9a0c-c7857fd3fd6c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003359.4(UGDH):c.1248G>C (p.Glu416Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2894969"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8d3d2cd6-0638-4555-afbd-702e28ec81a8","type":"EvidenceLine","dc:description":"gnomAD v4. MAF was 0.01886 (1415/75032, 9 homozygotes) in African/ African American which is too frequent to be pathogenic (>0.00001)","calculatedScore":0.5,"direction":"Contradicts","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8d3d2cd6-0638-4555-afbd-702e28ec81a8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Thermally sensitive fluorescence assay showed that protein stability is compromised by the variants that occur at the dimer interface (PMID: 22815472)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/8d3d2cd6-0638-4555-afbd-702e28ec81a8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19506109","allele":{"id":"https://genegraph.clinicalgenome.org/r/8325e84c-c20b-49c1-92a4-d32421964887","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003359.4(UGDH):c.421C>T (p.Arg141Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2895153"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":0}],"evidenceStrength":"Disputed","sequence":8845,"specifiedBy":"GeneValidityCriteria10","strengthScore":2.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/xWFdbiasNJM","type":"GeneValidityProposition","disease":"obo:MONDO_0005453","gene":"hgnc:12525","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_ecce1706-83f5-4a2e-8f15-3a2207972a69-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}